 Benzhydryl Compounds
"Benzhydryl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.
| Descriptor ID |
D001559
|
| MeSH Number(s) |
D02.455.426.559.389.115
|
| Concept/Terms |
Benzhydryl Compounds- Benzhydryl Compounds
- Compounds, Benzhydryl
- Diphenylmethyl Compounds
- Compounds, Diphenylmethyl
|
Below are MeSH descriptors whose meaning is more general than "Benzhydryl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzhydryl Compounds".
This graph shows the total number of publications written about "Benzhydryl Compounds" by people in this website by year, and whether "Benzhydryl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2004 | 1 | 2 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 2 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 0 | 2 | | 2011 | 1 | 1 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 6 | 1 | 7 | | 2018 | 4 | 2 | 6 | | 2019 | 2 | 2 | 4 | | 2020 | 4 | 3 | 7 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 0 | 1 | | 2024 | 2 | 2 | 4 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzhydryl Compounds" by people in Profiles.
-
Mahmud FH, Bjornstad P, Clarson C, Clarke A, Anthony SJ, Curtis J, Elia YT, McArthur L, Mertens L, Moineddin R, Kirsch S, Coles N, Maione M, Furman M, Babalola F, Tommerdahl KL, Harrington J, Riddell MC, Prasad P, Huang L, Heerspink HJL, Cherney DZI. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial. Nat Med. 2025 Jul; 31(7):2317-2324.
-
Beernink JM, Jongs N, Mosterd CM, Scholtes RA, Caldwell-McGee A, Casillas D, Driscoll L, Greasley PJ, Karlsson C, Hammarstedt A, Sridhar VS, Muskiet MHA, Laverman GD, Cherney DZI, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes Obes Metab. 2025 Aug; 27(8):4415-4426.
-
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 Jul; 27(7):3943-3956.
-
Miller RL, Wang Y, Aalborg J, Alshawabkeh AN, Bennett DH, Breton CV, Buckley JP, Dabelea D, Dunlop AL, Ferrara A, Gao G, Gaylord A, Gold DR, Hartert T, Hertz-Picciotto I, Hoepner LA, Karagas M, Karr CJ, Kelly RS, Khatchikian C, Liu M, Meeker JD, O'Connor TG, Peterson AK, Sathyanarayana S, Sordillo J, Trasande L, Weiss ST, Zhu Y. Prenatal exposure to environmental bisphenols over time and their association with childhood asthma, allergic rhinitis and atopic dermatitis in the ECHO consortium. Environ Pollut. 2025 Feb 01; 366:125415.
-
Prueitt RL, Goodman JE. Evidence evaluated by European Food Safety Authority does not support lowering the temporary tolerable daily intake for bisphenol A. Toxicol Sci. 2024 Mar 26; 198(2):185-190.
-
Kugathasan L, Sridhar VS, Lovblom LE, Matta S, Saliba A, Debnath S, AlAkwaa FM, Nair V, Bjornstad P, Kretzler M, Perkins BA, Sharma K, Cherney DZI. Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 Diabetes. Diabetes. 2024 Mar 01; 73(3):401-411.
-
Cunningham JW, Claggett BL, Lopes RD, McMurray JJV, Perkovic V, Carroll K, Hiemstra T, Khavandi K, Lukas MA, Ranganathan P, Shannon J, van Adelsberg J, Singh AK, Solomon SD. Daprodustat and Heart Failure in CKD. J Am Soc Nephrol. 2024 May 01; 35(5):607-617.
-
Prueitt RL, Hixon ML, Fan T, Olgun NS, Piatos P, Zhou J, Goodman JE. Systematic review of the potential carcinogenicity of bisphenol A in humans. Regul Toxicol Pharmacol. 2023 Aug; 142:105414.
-
Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab. 2022 08; 24(8):1578-1587.
-
Kurtz R, Libby A, Jones BA, Myakala K, Wang X, Lee Y, Knoer G, Lo Cascio JN, McCormack M, Nguyen G, Choos END, Rodriguez O, Rosenberg AZ, Ranjit S, Albanese C, Levi M, Ecelbarger CM, Shepard BD. Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. Int J Mol Sci. 2022 May 18; 23(10).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|